FibroGen Reports Third Quarter 2024 Financial Results
FibroGen, Inc (FGEN)
Last fibrogen, inc earnings: 3/2 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=253783&p=irol-irhome
Company Research
Source: GlobeNewswire
Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) are expected in 1H 2025Initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC anticipated in 1Q 2025Third quarter net revenue growth of 15% year over year, driven by strong performance of roxadustat in China, with year over year volume growth of 34% Reiterate full year net product revenue guidance of $135 million to $150 million, representing full year total roxadustat net sales in China1 between $330 million to $350 million Meaningful progress on U.S. cost reduction plan Expected to be substantially complete by year-end 2024 Cash, cash equivalents and accounts receivable balance of $160.0 million SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financ
Show less
Read more
Impact Snapshot
Event Time:
FGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FGEN alerts
High impacting FibroGen, Inc news events
Weekly update
A roundup of the hottest topics
FGEN
News
- FibroGen, Inc. (NASDAQ: FGEN) had its "market perform" rating re-affirmed by analysts at William Blair.MarketBeat
- FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost Reductions [Yahoo! Finance]Yahoo! Finance
- FibroGen, Inc. (NASDAQ: FGEN) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- FibroGen to Report Third Quarter 2024 Financial ResultsGlobeNewswire
- FibroGen, Inc. (NASDAQ: FGEN) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
FGEN
Earnings
- 11/12/24 - Beat
FGEN
Sec Filings
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- 11/12/24 - Form SC
- FGEN's page on the SEC website